Mats Någård (Mats Nagard)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Randomized Controlled Trial

Magnetic Resonance

Top Venues

Cancer chemotherapy and pharmacology

Clinical kidney journal

CPT: pharmacometrics & systems pharmacology

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Lindsay E Clegg, Lulu Chu, Mats Någård, David W Boulton, Robert C Penland
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study. CPT: pharmacometrics & systems pharmacology (2023)
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Dinko Rekić, Corina Dota, Lone H Ottesen, Yan Li, Ganesh M Mugundu
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study. Cancer chemotherapy and pharmacology (2023)
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran, Laura Nadeau, William J Edenfield, Lionel D Lewis, Lone H Ottesen, Yan Li, Ganesh M Mugundu
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer chemotherapy and pharmacology (2023)
Mats Någård, Nurul Choudhury, Ayman Al-Shurbaji, Vera Lisovskaja, Neil Mackillop
A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin. Clinical kidney journal 16 (1) (2022)
Mats Någård, Nurul Choudhury, Ayman Al-Shurbaji, Vera Lisovskaja, Neil Mackillop
A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin. Clinical kidney journal 16 (1) (2022)
M Daniel Naagaard, Roy Chang, Mats Någård, Weifeng Tang, David W Boulton
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. British journal of clinical pharmacology (2021)